The Million Women Study is a cohort study involving 1.3 million women in the UK, funded by Cancer Research UK and the Medical Research Council, and run in collaboration with the National Health Service Breast Screening Programme. Its main aim is to investigate the effect of hormone replacement therapy (HRT) on women’s health.
EPIC – the European Prospective Investigation into Cancer and Nutrition is a prospective study designed to investigate the relationships between diet and other lifestyle factors and the incidence of different forms of cancer. The total cohort involves over half a million men and women from ten European countries. The EPIC-Oxford cohort consists of 65,000 men and women living throughout the United Kingdom.
We have developed an online diet questionnaire, the Oxford WebQ, which asks you about what you had to eat and drink the previous day. We would like you to help us understand how accurately our questionnaire measures your diet in comparison with your four day diet record that you completed as part of the National Diet and Nutrition Survey (NDNS).
The Collaborative Group on Hormonal Factors in Breast Cancer conducts pooled analyses of data on breast cancer from 85 studies from approximately 30 countries worldwide. Set up in 1992, major publications have included analyses on hormonal contraceptives (1996), hormone replacement therapy (1997) and abortion (2004).
The Collaborative Group on Epidemiological Studies of Ovarian Cancer includes data on 30,000 women with ovarian cancer from 45 studies worldwide. The first analyses, published in 2008, showed that use of hormonal contraceptives confers long-lasting protection against ovarian cancer. Further analyses are planned on hormonal factors such as use of hormone replacement therapy and reproductive factors.
The Collaboration on Epidemiological Studies of Endometrial Cancer conducts pooled analyses of international data on endometrial cancer. Set up in 2005, the collaboration currently includes data on over 14,000 women with endometrial cancer from 24 studies worldwide. Several research projects are on-going investigating the role of hormonal, reproductive and other factors on the risk of the disease.
The Endogenous Hormones and Breast Cancer Collaborative Group conducts pooled analyses of endogenous (natural) hormones in relation to breast cancer risk. Scientists from 18 studies around the world are collaborating in this work, and the group is looking at the roles of oestrogens, androgens and growth factors in the aetiology of breast cancer.
The Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group conducts pooled analyses of the relationship between endogenous sex hormones, insulin-like growth factors and subsequent prostate cancer risk and includes collaborations with scientists from 40 studies world-wide.
The HIV and Cancer Collaborative Group conducts pooled analyses of HIV infection in relation to risk for cancer, bringing together the worldwide evidence from case-control and cohort studies.
Cervical cancer is the focus for several studies looking primarily at the relationships between hormones, including use of oral contraceptives and hormone replacement therapy, and risk of cancer of the cervix.
Members of the Cancer Screening Programmes Research Group work on a number of studies relating to breast, cervical and bowel screening. The unit has recently contributed to the European Guidelines for quality assurance in colorectal cancer screening (European Commission, 2011) and to an international collaborative project on evaluation of colorectal cancer screening, the International Colorectal Cancer Screening Network (ICRCSN) (Benson et al., 2011, Atkin et al., 2010, Benson et al., 2009) Current research projects include a study of factors related to testing false positive in the NHS Bowel Cancer Screening Programme (The Bowel Screening Follow-Up Study) and a large randomised trial of extending the age for breast screening (NHSBSP Age Extension Trial).
Our data access policies.